RecruitingPhase 3NCT05183035
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Studying Acute promyelocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- PedAL BCU, LLC
- Principal Investigator
- Seth Karol, MDSt. Jude Children's Research Hospital
- Intervention
- Fludarabine(drug)
- Enrollment
- 130 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 2022 – 2031
Study locations (30)
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- MemorialCare Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
- Children's Hospital of Orange County Main Campus - Orange, Orange, California, United States
- Benioff Children's Hospital - Mission Bay, San Francisco, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Yale University, New Haven, Connecticut, United States
- Nemours Alfred I. Dupont Hospital for Children, Wilmington, Delaware, United States
- Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
- University of Florida Health Shands Children's Hospital, Gainesville, Florida, United States
- Nemours Children's Specialty Care Jacksonville, Jacksonville, Florida, United States
- Nemours Children's Hospital - Orlando, Orlando, Florida, United States
- Saint Joseph's Hospital - Tampa, Tampa, Florida, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Kapi'olani Medical Center for Women and Children, Honolulu, Hawaii, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Princess Maxima Center for Pediatric Oncology (European Sponsor) · AbbVie · Roche-Genentech · EuPAL
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05183035 on ClinicalTrials.govOther trials for Acute promyelocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07563179Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaShenzhen University General Hospital
- RECRUITINGPHASE3NCT07504458Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic LeukemiaQuetzal Therapeutics
- RECRUITINGPHASE3NCT07223814Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)Stichting Hemato-Oncologie voor Volwassenen Nederland
- ACTIVE NOT RECRUITINGNANCT07187505Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic LeukemiaAnhui Medical University
- RECRUITINGPHASE3NCT07503730Early Use of Realgar-Indigo Naturalis Formula (RIF) Combined With All-trans Retinoic Acid (ATRA) for Treating Acute Promyelocytic Leukemia (APL).First Affiliated Hospital Xi'an Jiaotong University
- ENROLLING BY INVITATIONNANCT06697327Daunorubicin + Cytarabine + Venetoclax in de Novo AMLAnhui Medical University
- RECRUITINGPHASE1NCT06313437Revumenib in Combination With 7+3 + Midostaurin in AMLRichard Stone, MD
- RECRUITINGPHASE3NCT06578247Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AMLDaiichi Sankyo